BCM
SRPT icon

Boxer Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Boxer Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7M Hold
150,000
– – 0.2% 53
2026
Q1 		$3.26M Hold
150,000
– – 0.43% 38
2025
Q4 		$3.23M Sell
150,000
-100,000
-40% -$2.11M 0.71% 34
2025
Q3 		$4.82M Buy
250,000
+225,000
+900% +$4.01M 1.54% 16
2025
Q2 		$428K Buy
+25,000
New +$1.07M 0.22% 18

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Boxer Capital Management's SRPT Position: Q2 2026 in Review

Boxer Capital Management held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 150,000 shares worth $2.7M. The position accounts for 0.2% of the portfolio, ranked #53.

Boxer Capital Management first reported a position in SRPT in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.82M in Q3 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Boxer Capital Management held 150,000 shares of Sarepta Therapeutics worth $2.7M as of Q2 2026.
  • Boxer Capital Management left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up 0.2% of Boxer Capital Management's portfolio in Q2 2026, its #53 holding.
  • Boxer Capital Management first reported a position in Sarepta Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Boxer Capital Management's Sarepta Therapeutics position peaked at $4.82M in Q3 2025.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.